Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31537746 | 0.98 | MAPT (0.55) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| Trifluoroacetic Acid SCHEMBL3488528 | 0.85 | VNN1 (0.48) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL30471916 | 0.82 | LOXL2 (0.59) | CYP3A4MAPTKDM4EKDM1AMAOA | |
| SCHEMBL25588020 | 0.82 | KDM1A (0.51) | LMNAKDM1AMAOAMAOBERCC1 | |
| SCHEMBL320058 | 0.82 | LOXL2 (0.59) | CYP3A4MAPTKDM4EKDM1AMAOA | |
| SCHEMBL13181742 | 0.81 | KDM1A (0.50) | LMNAKDM1AMAOAMAOBERCC1 | |
| SCHEMBL28584924 | 0.79 | CYP3A4 (0.71) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL409441 | 0.78 | SCN8A (0.56) | CYP3A4CYP1A2MAPK1MAPTKDM4E | |
| SCHEMBL15018259 | 0.78 | ERCC1 (0.49) | LMNAKDM1AMAOAMAOBERCC1 | |
| SCHEMBL6691560 | 0.78 | NOS1 (0.58) | CYP3A4CYP1A2MAPK1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-119899184-A | Beta-carboline compound, preparation method thereof and application thereof in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2025-04-29 | — | — | CN | disclosed |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | CORNELL UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| WO-2021046515-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-1989204-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| EP-1373234-B1 | UROKINASE INHIBITORS | WILEX AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2008002596-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007095628-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
| US-4076943-A | DIURETICS, SALURETICS, ANTIHYPERTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1978-02-28 | — | — | US | disclosed |
| US-4061653-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
| US-3950528-A | HYPOTENSIVE AGENTS, SALURETICS, DIURETICS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | CYP3A4 4773/4885CYP1A2 4782/4885PKM 2169/4885 |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA1 | CYP3A4 1749/4885CYP1A2 1308/4885PKM 4111/4885 |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | CYP3A4 752/4885CYP1A2 631/4885PKM 779/4885 |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | CYP3A4 4773/4885CYP1A2 4782/4885PKM 2169/4885 |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | PTGER1, LOXL1, COL1A1 | CYP3A4 254/4885CYP1A2 132/4885PKM 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.